NCT02438085Recruiting
Prospective Registry of Acute Coronary Syndromes in Ferrara
Acute coRonary sYndrOmes proSpective regisTry Of Ferrara
Source: ClinicalTrials.gov · Last updated 14 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The ARYOSTO has been designed to describe the clinical epidemiology and the current management of acute coronary syndromes (ACS) in the area of Ferrara. Especially, the Authors will evaluate the medical and interventional management of ACS patients admitted to hospitals in the area of Ferrara and receiving coronary artery angiography and percutaneous coronary intervention (PCI) in the hub center of Ferrara (Azienda Ospedaliera Universitaria di Ferrara, Cona (FE), Italy)
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 10000 (estimated)
- First submitted
- 30 Apr 2015
- Start date
- 1 Jun 2014
- Primary completion date
- 30 Nov 2028
- Lead sponsor
- University Hospital of Ferrara
- Diseases
- Coronary artery disease
- NCT number
- NCT02438085
What you commit to
- Study type: Observational
- Planned participants: 10000
- From 1 Jun 2014 to the primary completion date, 30 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- age \>18 years
- hospital admission for acute coronary syndromes
- resident in the Ferrara area
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Of Ferrara Coordinator of this site? Confirm its status | Cona | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.